MedTrace Logo

Randomised Controlled Trial of Electroconvulsive Therapy (ECT) in Relapse Prevention of Depression

NCT00627887 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2012-06-22

No results posted yet for this study

Summary

The purpose of the study is to determine if continuation electroconvulsive therapy (ECT) is safe and effective in relapse prevention of depression.

Conditions

  • Depressive Disorder, Major

Interventions

PROCEDURE

Electroconvulsive therapy

unilateral briefpulse ECT weekly for the first 6 weeks thereafter every 2 weeks for a total of one year

DRUG

venlafaxine

extended release target dose of 300mg/day duration of one year

DRUG

Lithium

serum concentration 0,5-0,8 mmol/L, one year duration

Sponsors & Collaborators

  • Uppsala-Örebro Regional Research Council

    collaborator OTHER

  • Örebro County Council

    lead OTHER_GOV

Principal Investigators

  • Ingemar Engstrom, MD, PhD · County Council of Orebro, University of Orebro, Sweden

  • Axel Nordenskjold, MD · County Council of Orebro,

  • Lars von Knorring, PhD, MD · County Council of Uppsala, University of Uppsala Sweden

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2012-05-31
Completion
2012-05-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00627887 on ClinicalTrials.gov